$AVEO News
Last published 2y ago
- 2y agoAFFYBEAMDASHLYFT+32024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and SpeakersBusiness WireThe Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate
- 3y agoAVEOLG Chem Completes Acquisition of AVEO OncologyGlobeNewswireSEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. ("LG Chem") (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology ("AVEO"), a commercial stage,
- 3y agoAVEOAVEO Oncology Stockholders Approve Acquisition by LG ChemGlobeNewswireBOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients
- 3y agoAVEOAVEO Oncology Reminds Stockholders to Vote "FOR" All-Cash Transaction with LG Chem in advance of the Special Meeting of StockholdersGlobeNewswireBOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology ("AVEO") (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients
- 4y agoAVEOAVEO Oncology Reports Third Quarter 2022 Financial ResultsGlobeNewswire– Total Q3 2022 Net Revenue of $30.4 million, including $30.2 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Announced entering a definitive agreement under which LG Chem will acquire AVEO for $15.00
- 4y agoAVEOLG Chem to Acquire AVEO Oncology for $15.00 Per Share in CashGlobeNewswireAcquisition Provides LG Chem's Life Sciences Division a Commercial Footprint in the U.S., Diversifies its Pipeline with a Broad Range of Oncology Therapies and Accelerates LG Chem's Efforts to Deliver Continued Growth
- 4y agoAVEOU.S. Patent & Trademark Office Allows AVEO Oncology's Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell CarcinomaGlobeNewswireBOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with
- 4y agoAVEOAVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc ConferenceGlobeNewswireBOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that Michael B
- 4y agoAVEOAVEO Oncology Announces Participation at Investor Conferences in SeptemberGlobeNewswireBOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of
- 4y agoAVEOAVEO Oncology Reports Second Quarter 2022 Financial ResultsGlobeNewswire– Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1 2022 – – Company Reaffirms Full Year
- 4y agoAVEOAVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022GlobeNewswireBOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022. AVEO's manage
- 4y agoAVEOAVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCCGlobeNewswire- This agreement follows AVEO's entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase
- 4y agoAVEOAVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) PatientsGlobeNewswireBOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 s
- 4y agoAVEOAVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual MeetingGlobeNewswireExploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib Latest analysis of Phase 2 study show tivozanib demons
- 4y agoAVEOAVEO Oncology Announces Participation at the H.C. Wainwright Global Investment ConferenceGlobeNewswireBOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright
- 4y agoAVEOAVEO Oncology Reports First Quarter 2022 Financial ResultsGlobeNewswire– Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Reaffirms Full Year 2022 FOTIVDA U
- 4y agoAVEOAVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022GlobeNewswireBOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO's managemen
- 4y agoAVEOAVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial ResultsGlobeNewswire– Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescription
- 4y agoAVEOAVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022GlobeNewswireBOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022. AVEO's management t
- 4y agoATNMAVEOActinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid TumorsPR NewswireNEW YORK and BOSTON, Feb. 22, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies and AVEO Oncology (NASDAQ:AVEO) ("AVEO"), a commercial stage, oncology-
- 4y agoAVEOAVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell CarcinomaGlobeNewswireFive year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to demonstrate durable disease control and positive tre
- 4y agoAVEOAVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireBOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SV
- 4y agoAVEOAVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers SymposiumGlobeNewswireFirst line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Pha
- 4y agoAVEONiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell CarcinomaBusiness Wire- Phase 2 Clinical Trial Targeted to Commence in 2022 - NiKang Therapeutics Inc. ("NiKang"), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncolo
- 4y agoAVEOAVEO Oncology Highlights Recent Progress and 2022 OutlookGlobeNewswireBOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. "I am proud of the entire AVEO team this ye
- 4y agoAVEOAVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCCGlobeNewswireBOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmsta
- 4y agoAVEOAVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 ConferenceGlobeNewswireBOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect
- 4y agoAVEOAVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating OfficerBusiness Wire- Former chief operating officer of Enzyvant Therapeutics brings over 20 years of biotech leadership experience - AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Lede
- 5y agoAVEOAVEO Oncology Announces Participation at Two Upcoming Virtual Investor ConferencesBusiness WireAVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two upcoming virtual investor conferences: Stifel 2021 Healthcare ConferenceD
- 5y agoAVEOBMSAVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire– Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $14.3 Million –– Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) –
- 5y agoAVEOAVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021Business WireAVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021. AVEO's management team will host a conference call and aud
- 5y agoAVEOEDSAFCELLCID+1Thinking about buying stock in Edesa Biotech, AVEO Pharmaceuticals, Lucid Group, FuelCell Energy, or Nikola Corp?PR NewswireNEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, AVEO, LCID, FCEL, and NKLA.
- 5y agoAVEOAVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell CarcinomaBusiness WireAVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with rel
- 5y agoAVEOAVEO Oncology Announces Participation at Two Upcoming Virtual Investor ConferencesBusiness WireAVEO Oncology (NASDAQ:AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13Time: 7:00 a.m.
- 5y agoAVEOAtezolizumab Plus Tivozanib in Immunologically Cold Tumor Types - NCT05000294ClinicalTrials.govObjective response rate (ORR), Progression free survival (PFS), Overall survival (OS), Disease control rate (DCR)
- 5y agoAVEOBMSAVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire– Total 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $6.7 Million – – Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO® (nivolumab) on Track to Initiate Enrollment in 3Q 2021 ��
- 5y agoAVEOAVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021Business WireAVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO's management team will host a conference cal
- 5y agoAVEOAVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell CarcinomaBusiness WireWebinar on Friday, July 16th at 12 p.m. Eastern Time FOTIVDA recently surpassed 300 total commercial prescriptions since its March 22, 2021 launch AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company,
- 5y agoAVEOAVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell CarcinomaBusiness WireWebinar on Wednesday, June 16 at 2:00 p.m. Eastern Time AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the C
- 5y agoAVEOAVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare ConferenceBusiness WireAVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time. A live webcast of the
- 5y agoAVEOAVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell CarcinomaBusiness Wire- Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up - - Analysis of TEAEs in TIVO-3 Study Shows Longer Time to Onset and Fewer Dose Reductions f
- 5y agoAVEOAVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCCBusiness Wire– Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX®) Combination – – 38% ORR, Including 13% CRs and 25% PRs, and Median PFS of 4.1 months Observed in HPV Negative Patients Treated with Ficlatuzum
- 5y agoAVEOAZNHTGCBMSAVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire– U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Dist
- 5y agoAVEOAVEO Pharmaceuticals, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 10, 2021 / AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 4:30 PM Eastern Time. To listen to the event live or ac
- 5y agoAVEOAVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021Business WireAVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021. AVEO's management team will host a conference call and
- 5y agoAVEOAVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of DirectorsBusiness WireBOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director ...
- 5y agoAVEOAVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice GuidelinesBusiness WireBOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma ( ...
- 5y agoAVEOAVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional SharesBusiness WireBOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the public of $8.00 per share. The aggregate gross proceeds to AVEO from the offering were $55. ...
- 5y agoAVEOAVEO Announces Pricing of $48.0 Million Public Offering of Common StockBusiness WireBOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. The gross proceeds to AVEO from the offering are expected to be $48.0 million before deducting underwriting discounts and commissions and offering expenses. All of the shar ...
- 5y agoAVEOAVEO Announces Proposed Public Offering of Common StockBusiness WireBOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subje ...